Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

1. Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026
   Review
2. CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas.Scientific reports · 2026
   Article
3. Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy.iScience · 2025
   Review
4. CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.Leukemia · 2022
   Article
5. Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.Frontiers in oncology · 2022
   Review
6. Intrauterine Hypoxia and Epigenetic Programming in Lung Development and Disease.Biomedicines · 2021
   Review
7. An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality.International journal of environmental research and public health · 2021
   Review
8. miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma.Haematologica · 2021
   Article
9. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.Cancers · 2021
   Review
10. Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology.Frontiers in oncology · 2021
    Article
11. ALK-transformed mature T lymphocytes restore early thymus progenitor features.The Journal of clinical investigation · 2020
    Article
12. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.Clinical epigenetics · 2020
    Review
13. High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells.Cancers · 2020
    Article
14. Ancestral stress programs sex-specific biological aging trajectories and non-communicable disease risk.Aging · 2020
    Article
15. Targeting epigenetic regulators in the treatment of T-cell lymphoma.Expert review of hematology · 2020
    Review
16. Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma.International journal of molecular sciences · 2019
    Review
17. Epigenetic Biomarkers in Cardiovascular Diseases.Frontiers in genetics · 2019
    Review
18. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.Cancer biomarkers : section A of Disease markers · 2019
    Article
19. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Targeted oncology · 2017
    Review
20. MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma.Oncotarget · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as